Showing results for
Vaccine Development

World Health Organization experts provide guidance on use of the Oxford vaccine

World Health Organization experts provide guidance on use of the Oxford vaccine

ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults

ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

Oxford leads first trial investigating dosing with alternating vaccines

Oxford leads first trial investigating dosing with alternating vaccines

Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose

Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose

European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine

European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

UK National Health Service begins rollout of Oxford coronavirus vaccine

UK National Health Service begins rollout of Oxford coronavirus vaccine

Oxford vaccine regulatory authorisation: FAQ

Oxford vaccine regulatory authorisation: FAQ

University of Oxford welcomes regulatory authorisation of coronavirus vaccine

University of Oxford welcomes regulatory authorisation of coronavirus vaccine